摘要
目的分析α-硫辛酸注射液治疗2型糖尿病患者周围神经病变的临床疗效及安全性,为临床治疗2型糖尿病周围神经病变提供可参考依据。方法选取2017年1月—2018年1月期间该院收治的2型糖尿病周围神经病变患者120例,按照随机数字表法分为对照组与实验组。对照组给予静脉滴注甲钴胺,实验组在对照组的基础上给予α-硫辛酸注射液治疗。治疗后,比较两组患者的临床疗效、神经传导速度、周围神经病变的症状评分(TSS)及不良反应发生情况。结果治疗组有效率为86.67%明显大于对照组的65.00%(χ~2=6.373,P<0.05)。实验组患者正中神经和腓总神经运动神经传导速度(MCV)及感觉神经传导速度(SCV)比治疗前显著提高,且实验组效果优于对照组,治疗后观察组的TSS评分情况显著优于对照组(t=5.023,P<0.05)。两组患者在治疗期间均无明显的不良反应。结论采用α-硫辛酸注射液治疗2型糖尿病周围神经病变患者的临床效果显著,能够有效的改善患者的临床症状,且无明显不良反应,安全性高,值得临床推广应用。
Objective To analyze the clinical efficacy and safety of α-lipoic acid injection in the treatment of peripheral neuropathy in patients with type 2 diabetes, and to provide reference for the clinical treatment of type 2 diabetic peripheral neuropathy. Methods A total of 120 patients with type 2 diabetic peripheral neuropathy admitted to our hospital from January 2017 to January 2018 were enrolled in the control group and the experimental group according to the random number table method. The control group was given an intravenous infusion of mecobalamin, and the experimental group was treated with α-lipoic acid injection on the basis of the control group. After treatment, the clinical efficacy, nerve conduction velocity, symptom score(TSS) of peripheral neuropathy, and adverse reactions were compared between the two groups. Results The effective rate of the treatment group was 86.67%, which was significantly higher than that of the control group(65.00%)(χ^2=6.373,P<0.05). In the experimental group, the median nerve and common peroneal nerve motor conduction velocity(MCV) and sensory nerve conduction velocity(SCV) were significantly higher than those before treatment, and the experimental group was better than the control group. The TSS score of the observation group was significantly better after treatment than the control group(t=5.023,P<0.05). There were no significant adverse reactions during the treatment period between the two groups of patients. Conclusion The clinical effect of α-lipoic acid injection in the treatment of patients with type 2 diabetic peripheral neuropathy is significant, which can effectively improve the clinical symptoms of patients, without obvious adverse reactions, high safety, and worthy of clinical application.
作者
侯华正
HOU Hua-zheng(Department of General Internal Medicine, Central Hospital of Heze Development Zone, Heze, Shandong Province, 274000 China)
出处
《系统医学》
2019年第3期38-39,42,共3页
Systems Medicine
